NASDAQ:MIST - Nasdaq - CA59935V1076 - Common Stock - Currency: USD
NASDAQ:MIST (4/28/2025, 9:53:49 AM)
1.2798
0 (-0.02%)
The current stock price of MIST is 1.2798 USD. In the past month the price decreased by -43.11%. In the past year, price decreased by -16.88%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.08 | 826.66B | ||
JNJ | JOHNSON & JOHNSON | 15.35 | 371.72B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.12 | 277.44B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.14 | 221.72B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.99 | 218.54B | ||
MRK | MERCK & CO. INC. | 10.58 | 207.46B | ||
PFE | PFIZER INC | 7.45 | 131.49B | ||
SNY | SANOFI-ADR | 13.75 | 129.60B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.57 | 98.08B | ||
GSK | GSK PLC-SPON ADR | 8.7 | 76.72B | ||
ZTS | ZOETIS INC | 26.02 | 68.70B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.8 | 47.49B |
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
MILESTONE PHARMACEUTICALS IN
420-1111 boul. Dr.-Frederik-Philips
MONTREAL QUEBEC H4M 2X6 CA
CEO: Joseph Oliveto
Employees: 47
Company Website: https://www.milestonepharma.com
Investor Relations: http://investors.milestonepharma.com
Phone: 15143360444
The current stock price of MIST is 1.2798 USD. The price decreased by -0.02% in the last trading session.
The exchange symbol of MILESTONE PHARMACEUTICALS IN is MIST and it is listed on the Nasdaq exchange.
MIST stock is listed on the Nasdaq exchange.
10 analysts have analysed MIST and the average price target is 5.1 USD. This implies a price increase of 298.5% is expected in the next year compared to the current price of 1.2798. Check the MILESTONE PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MILESTONE PHARMACEUTICALS IN (MIST) has a market capitalization of 68.28M USD. This makes MIST a Micro Cap stock.
MILESTONE PHARMACEUTICALS IN (MIST) currently has 47 employees.
MILESTONE PHARMACEUTICALS IN (MIST) has a resistance level at 1.29. Check the full technical report for a detailed analysis of MIST support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MIST does not pay a dividend.
MILESTONE PHARMACEUTICALS IN (MIST) will report earnings on 2025-05-19, before the market open.
MILESTONE PHARMACEUTICALS IN (MIST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
The outstanding short interest for MILESTONE PHARMACEUTICALS IN (MIST) is 5.02% of its float. Check the ownership tab for more information on the MIST short interest.
ChartMill assigns a fundamental rating of 1 / 10 to MIST. MIST may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months MIST reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS increased by 50.43% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -54.99% | ||
ROE | -315.81% | ||
Debt/Equity | 4.06 |
ChartMill assigns a Buy % Consensus number of 80% to MIST. The Buy consensus is the average rating of analysts ratings from 10 analysts.